|1.||Anaphylaxis (Anaphylactic Shock)
|2.||Food Hypersensitivity (Food Allergy)
|3.||Peanut Hypersensitivity (Peanut Allergy)
|1.||Burks, A Wesley: 25 articles (05/2015 - 01/2002)|
|2.||Sampson, Hugh A: 25 articles (05/2015 - 05/2002)|
|3.||Wood, Robert A: 17 articles (05/2015 - 07/2003)|
|4.||Lack, Gideon: 12 articles (05/2015 - 03/2003)|
|5.||Sicherer, Scott H: 11 articles (05/2015 - 07/2003)|
|6.||Jones, Stacie M: 10 articles (05/2015 - 08/2009)|
|7.||Turcanu, Victor: 8 articles (05/2015 - 04/2010)|
|8.||Sampson, H A: 8 articles (06/2013 - 07/2000)|
|9.||Dreskin, Stephen C: 7 articles (05/2015 - 12/2010)|
|10.||Li, Xiu-Min: 7 articles (12/2014 - 07/2003)|
|1.||Immunoglobulin E (IgE)IBA
05/01/2012 - "Individuals with peanut allergy showed significantly greater IgE binding and broader epitope diversity than did peanut-tolerant individuals. "
06/01/2002 - "Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays."
04/01/2015 - "IgE recognition patterns in peanut allergy are age dependent: perspectives of the EuroPrevall study."
01/01/2013 - "The aim of this study was to examine the possible association between peanut allergen IgE components and severity of clinical reactions in patients with a history of peanut allergy. "
01/01/2012 - "Randomised controlled trials (RCTs), quasi-RCTs or controlled clinical trials involving children or adults with clinical features indicative of IgE-mediated peanut allergy treated with allergen-specific OIT, compared with control group receiving either placebo or no treatment, were eligible for inclusion. "
|2.||hypoxanthine arabinoside (ara-H)IBA
02/01/2008 - "Alleviating peanut allergy using genetic engineering: the silencing of the immunodominant allergen Ara h 2 leads to its significant reduction and a decrease in peanut allergenicity."
10/01/2015 - "Ara h 2 and Ara 6 are the best predictors of severe peanut allergy: a double-blind placebo-controlled study."
12/01/2004 - "We sought to study the occurrence of peanut allergy in patients allergic to birch pollen and characterized the Bet v 1-homologous peanut allergen Ara h 8. Recombinant Ara h 8 was cloned with degenerated primers and expressed in Escherichia coli. "
11/01/2015 - "Utility of Ara h 2 sIgE levels to predict peanut allergy in Canadian children."
11/01/2015 - "These findings suggest a method for use of the seed aspartic protease in reducing peanut allergy due to Ara h 1. "
11/01/2004 - "Improved understanding of the molecular structure of the major peanut allergens and the peanut-specific immune response has lead to significant diagnostic and therapeutic advances in the study of peanut allergy."
06/01/2000 - "The development of improved methods for diagnosis and treatment of peanut allergies requires a better understanding of the structure of the allergens. "
11/01/2015 - "These allergens need to be discovered to allow estimation of the allergenic risk for patients with peanut allergy and to further improve diagnostic measures. "
01/01/2013 - "For this reason, the information available on peanut allergens is increasing and the debate about peanut allergy is always renewed. "
01/01/2013 - "This fact has originated the publication of an elevated number of scientific reports dealing with peanut allergens and, especially, the prevalence of peanut allergy. "
|4.||Proteins (Proteins, Gene)IBA
11/01/2015 - "The proteins were able to activate basophils of patients with peanut allergy. "
11/01/2015 - "Proteins were studied by using SDS-PAGE and immunoblotting with sera from patients with peanut allergy. "
01/01/2015 - "We determined the individual contribution of peanut proteins to B, T cell and allergic effector responses in a mouse model for peanut allergy. "
09/01/2014 - "Loss of allergenic proteins during boiling explains tolerance to boiled peanut in peanut allergy."
03/01/2014 - "Sensitizing potential of enzymatically cross-linked peanut proteins in a mouse model of peanut allergy."
02/01/2012 - "The aim of the study was to evaluate the basophil allergen threshold sensitivity (CD-sens) and antibodies to peanut allergen components in relation to DBPCFC in the diagnoses of peanut allergy in children. "
05/01/2013 - "We measured concentration and avidity of antibodies to 12 pneumococcal serotypes in 78 children aged 0.6-18 years with recurrent bacterial respiratory infections, and in 80 individuals who were being tested for peanut allergy, ages 0.4-15 years, serving as a comparison group. "
03/01/2008 - "Remission of peanut allergy can be predicted by low levels of IgE antibodies to peanut in the first 2 years of life or decreasing levels of IgE sensitization by the age of 3 years."
10/01/2004 - "The aim of the study was to investigate the development of peanut hypersensitivity in children and adolescents with specific IgE antibodies to peanut, using questionnaires and current serum tests and comparing it to information obtained 5-6 yr earlier, to investigate how peanut intake during this period related to subject age, IgE antibody levels and symptoms and to investigate what information this patient group was given at the time of diagnosis regarding avoidance of peanut related food. "
07/01/2015 - "Only limited evidence is available regarding the cytokine repertoire of effector T cells associated with peanut allergy, and how these responses relate to IgE antibodies to peanut components. "
08/01/2013 - "I argue that the peanut allergy epidemic was co-constructed through interactions between experts, publics, biomedical categories, and institutions, while social reactions to the putative epidemic expanded the sphere of surveillance and awareness of peanut allergy risk. "
05/01/2013 - "In the therapeutic model, co-administration of type B ODN plus peanut proteins was highly effective in reducing anaphylactic reactions in mice with established peanut allergy. "
|7.||Pepsin A (Pepsin)IBA
08/01/1999 - "In contrast, pepsin-digested peanut induced significant T-cell proliferation responses (stimulation index = 30) in vitro in PBMCs from 7 subjects with peanut allergy, albeit at lower levels than that induced by intact peanut (stimulation index = 66). "
08/01/1999 - "Western blot analysis of sera from 5 subjects with peanut allergy showed multiple IgE-reactive proteins in crude intact peanut extract that were eliminated after pepsin treatment of the peanut extract. "
|8.||HLA-DR Antigens (HLA-DR)IBA
01/01/2015 - "Here we conduct the first genome-wide association study of well-defined FA, including specific subtypes (peanut, milk and egg) in 2,759 US participants (1,315 children and 1,444 parents) from the Chicago Food Allergy Study, and identify peanut allergy (PA)-specific loci in the HLA-DR and -DQ gene region at 6p21.32, tagged by rs7192 (P=5.5 × 10(-8)) and rs9275596 (P=6.8 × 10(-10)), in 2,197 participants of European ancestry. "
12/01/2015 - "However, a recent large genomewide association study of patients with peanut allergy and their family members found 2 PA-associated single-nucleotide polymorphisms (rs9275596 and rs7192) mapping to regions involving the HLA-DR and HLA-DQ genes. "
12/01/2015 - "Early studies using candidate gene approaches found associations between PA and HLA-DR and -DQ alleles (HLA-DRB1*08 and DQB1*06:03P) when comparing subjects with peanut allergy with nonallergic unrelated control groups. "
10/01/2015 - "In addition, HLA-DR and HLA-DQ gene region variants appear to play a role in peanut allergy, although no studies have yet assessed their susceptibility to environmental cues. "
|9.||omalizumab (Xolair)FDA Link
05/01/2011 - "A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy."
12/01/2013 - "Among children with high-risk peanut allergy, treatment with omalizumab may facilitate rapid oral desensitization and qualitatively improve the desensitization process."
11/01/2012 - "Subjects with peanut allergy were treated with omalizumab for 6 months and assessed for clinical and cellular responses. "
11/01/2012 - "Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy."
11/01/2012 - "In subjects with peanut allergy, the basophil response appears to mitigate against the ability of omalizumab to improve the patient's tolerance of oral allergen."
03/01/2011 - "Filaggrin loss-of-function mutations showed a strong and significant association with peanut allergy in the food challenge-positive patients (P = 3.0 × 10(-6); odds ratio, 5.3; 95% CI, 2.8-10.2), and this association was replicated in the Canadian study (P = 5.4 × 10(-5); odds ratio, 1.9; 95% CI, 1.4-2.6). "
10/01/2015 - "Environmental peanut exposure has been associated with increased peanut allergy risk in individuals with filaggrin null mutations, consistently with sensitization occurring through a damaged skin barrier. "
10/01/2014 - "Filaggrin (FLG) loss-of-function mutations lead to an impaired skin barrier associated with peanut allergy. "
10/01/2014 - "Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations."
03/01/2011 - "To investigate the association between filaggrin loss-of-function mutations and peanut allergy. "
01/01/2005 - "The development of safe and effective immunotherapy for peanut allergy has been complicated by the high anaphylactic potential of native peanut extracts. "
04/12/2014 - "Small studies suggest peanut oral immunotherapy (OIT) might be effective in the treatment of peanut allergy. "
05/01/2013 - "A model of peanut allergy in C3H/HeJ mice was used to assess whether type A, B, or C CpG oligodeoxynucleotide (ODN) molecules would be effective in: (i) a prophylactic approach to prevent peanut allergy when administered simultaneously with a Th2-skewing adjuvant, and (ii) a therapeutic model to allow for shortened immunotherapy. "
05/01/2015 - "Although promising results have emerged regarding oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) for the treatment of peanut allergy (PA), direct comparisons of these approaches are limited. "
11/01/2014 - "Assessing the Efficacy of Oral Immunotherapy for the Desensitisation of Peanut Allergy in Children (STOP II): A Phase 2 Randomised Controlled Trial."
06/01/2013 - "This review discusses recent advances in molecular diagnostic techniques for peanut allergy and highlights advances in peanut allergy therapeutics, discussing allergen-specific and allergen-nonspecific treatments that are currently in Phase I/II clinical trials."
10/01/2011 - "The prevalence of peanut allergy appears to be on the rise worldwide, yet there are no therapeutics currently available that can alter the course of this condition. "
01/01/2015 - "Awareness about the relative contribution of individual peanut allergens and cross reactivity between these allergens is of importance for current research in diagnostics and therapeutics for and the mechanism of peanut allergy."
05/01/2004 - "Peanut allergy: sensitization by peanut oil-containing local therapeutics seems unlikely."
|3.||Transplantation (Transplant Recipients)
12/01/2011 - "Two mechanisms may explain the observations described for the patient reported in this study: de novo development of peanut allergies after transplantation, or passive transfer of peanut allergies from a peanut-sensitized organ donor. "
10/01/2008 - "Transfer of peanut allergy from the donor to a lung transplant recipient."
04/01/2007 - "In one epidemiological trial, an association between topical use of skin care products containing peanut oil and the development of peanut allergy was observed; however, the data reflect a retrospective analysis without specifying skin care products containing peanut oil and also without analysing the quantity of topicals used. "
|5.||Phytotherapy (Herbal Therapy)